Informing optimal first-line antihypertensive therapy: A rigorous comparative effectiveness analysis of ARBs vs. ACEIs on long-term risk of dementia, cancer, heart disease, and quality of life

为最佳一线抗高血压治疗提供信息：ARB 与 ACEI 对痴呆、癌症、心脏病和生活质量长期风险的严格比较有效性分析

• 批准号: 10340245
• 负责人: Adam P Bress
• 金额: $ 80.87万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-15 至 2025-12-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10340245
• 关键词: Accounting; Address; Adult; Affect; Aging; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Angiotensin II Receptor; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; California; Cardiovascular Diseases; Chronic Disease; Clinical; Code; Cognition; Cognitive; Comprehensive Health Care; Coronary; Data; Data Analyses; Data Sources; Dementia; Drug Prescriptions; Electronic Health Record; Event; Fibrosis; Goals; Guidelines; Health; Health Benefit; Heart Diseases; Heart failure; Hypertension; Incidence; Individual; Inflammation; Knowledge; Life Expectancy; Long-Term Effects; Longevity; Malignant Neoplasms; Methods; Modernization; Morbidity - disease rate; Myocardial Infarction; Natural Language Processing; Organ; Outcome; Oxidative Stress; Patient-Focused Outcomes; Patients; Persons; Pharmaceutical Preparations; Pharmacoepidemiology; Pharmacology; Physiological; Population; Prevalence; Public Health; Quality of life; Race; Randomized Controlled Trials; Regimen; Renin-Angiotensin System; Research; Risk Factors; Safety; Socioeconomic Status; Stroke; Subgroup; Time; Veterans; Veterans Health Administration; active comparator; base; comparative; comparative effectiveness analysis; cost efficient; dementia risk; design; experience; follow-up; frailty; improved; interest; medication compliance; modifiable risk; mortality; multiple chronic conditions; patient oriented; population health; prevent; sex; treatment adherence; treatment effect; vasoconstriction

PROJECT SUMMARY Hypertension (HTN) prevalence increases with aging and is a leading risk factor for several chronic illnesses including Alzheimer's disease and related dementias (ADRD), cardiovascular disease (CVD), and several cancers, as well as mortality. Angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) are two of the most commonly prescribed anti-HTN classes, used by ~40 million US adults. ARBs and ACEIs and have distinctive beneficial downstream effects on physiologic abnormalities in HTN, including vasoconstriction, inflammation, fibrosis, and oxidative stress, which in turn may result in different long-term risks of ADRD and multimorbidity associated with aging. However, current HTN guidelines recommend prescribing ARBs and ACEIs interchangeably due to presumed equivalent benefit and safety. Our goal is to optimize initial anti-HTN medication prescribing by clarifying the optimal first choice RAS-blocker between ARBs vs. ACEIs. Because ~23 million US adults are currently taking an ACEI and physiologic evidence supports differences in downstream effects of these medications, even if ARBs are only 15% more effective, the long-term population health impact of switching first-line RAS-blockade from ACEI to ARB would be enormous. We will leverage data from the Veterans Health Administration (VHA) and Kaiser Permanente Southern California (KP SoCal) to evaluate the effects of ARBs vs. ACEIs on the risk of ADRD, multimorbidity, frailty, and health-adjusted life expectancy (HALE; the amount of time one can expect to live accounting for one's cumulative morbidity burden). The VHA and KP SoCal are ideal data sources to perform this research because they include comprehensive healthcare information for >10 million patients, collect detailed information on medication use and health outcomes, and have high patient retention with >10 years of follow- up. The specific aims are to determine long-term comparative effects, including duration of use, of ARB- vs. ACEI-based anti-HTN medication regimens on (Aim 1) the incidence of ADRD, CVD (stroke, myocardial infarction, coronary revascularization, or heart failure), and cancers, separately and (Aim 2) the patient- centered outcome of frailty and the population-centered outcome of HALE. We will use an active comparator, new-user design accounting for medication adherence, as well as natural language processing to ascertain ADRD more accurately in the electronic health record over using administrative codes alone. Our team is well- suited to perform the study given considerable prior experience analyzing VHA and KP data, including pharmacoepidemiologic analyses of anti-HTN medication use; assessment of ADRD, CVD incidence, cancer incidence, and multimorbidity; and application of causal inference methods. Our project could support a paradigm shift of first-choice RAS-blockade. Current projections indicate that ADRD will affect >115 million people by 2050 and cancer incidence will be 27 million per year by 2040. The potential public health benefit of addressing these knowledge gaps and, thereby, improving the quality and length of life is enormous.

项目总结